To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets

Sandoz

Status and phase: Completed; Phase 1

Conditions: Depression

Treatments: Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories); Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00913822

870609D

Details and patient eligibility

About

To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.

Enrollment: 36 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

1

Experimental group

Description:

Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)

Treatment:

Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)

2

Active Comparator group

Description:

Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)

Treatment:

Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)